The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aESTEEM 1 study. Full analysis set, LOCF.
bP < 0.0001.
Response was maintained with OTEZLA through week 321
Baseline
Week 16 PASI-75 result
Individual results may vary.
*Actual real-world OTEZLA patient. Property of Amgen Inc.
BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index.
aLIBERATE study. ITT, LOCF.
bP <0.0001, OTEZLA vs placebo.
cIncludes patients who entered and were treated in the OTEZLA extension phase.
Response was maintained with OTEZLA for up to 2 years in biologic-naïve patients
Baseline
Week 16 PASI-80 result
Individual results may vary.
†In biologic-naïve patients with moderate to severe plaque psoriasis.
‡Actual real-world OTEZLA patient. Property of Amgen Inc.
ITT, intent to treat; LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
